US FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-and-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA has approved AKEEGA™ for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC.